2-11-2024, 02:00

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
Globe Newswire2-11-2024, 02:00
22-10-2024, 18:00

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Globe Newswire22-10-2024, 18:00
8-10-2024, 18:00

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
Globe Newswire8-10-2024, 18:00
3-10-2024, 19:30

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
Globe Newswire3-10-2024, 19:30
21-09-2024, 15:15

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
Globe Newswire21-09-2024, 15:15
21-09-2024, 15:10

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
Globe Newswire21-09-2024, 15:10